Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Akiko Rokudai"'
Autor:
Kiyotsugu Kojima, Ryoko Utsubo-Kuniyoshi, Natsuhiko Sugimura, Akiko Rokudai, Kiyohiko Hatake, Yoshiko Sonoda, Tadashi Kasahara, Yuko Mishima, Yuji Mishima, Yasuhito Terui
Publikováno v:
Cancer Science. 98:569-576
Small ubiquitin-related modifier (SUMO) modification appears to regulate the activity, intracellular localization, and stability of the targeted proteins. To explore the relationship among sumoylation, antitumor reagent, and apoptosis, we treated gre
Autor:
Kiyohiko Hatake, Tadashi Kasahara, Yoshiko Sonoda, Eriko Aizu-Yokota, Ryoko Kuniyoshi, Yuko Mishima, Yasuhito Terui, Akiko Rokudai, Yuji Mishima
Publikováno v:
Biological and Pharmaceutical Bulletin. 29:1102-1109
Allergic asthma and allergic dermatitis are chronic inflammatory diseases and are characterized by an accumulation of eosinophils at sites of inflammation. Eotaxin-1/CCL11 and eotaxin-3/CCL26 are members of the CC chemokine family, which are known to
Autor:
Yuko Matsumoto-Mishima, Yasuhito Terui, Kiyohiko Hatake, Natsuhiko Sugimura, Akiko Rokudai, Ryoko Kuniyoshi, Yuji Mishima
Publikováno v:
Cancer science. 98(3)
CD13/aminopeptidase-N (CD13/APN) is an important regulator of angiogenesis where its expression on activated blood vessels is induced by angiogenic signals. A previous study demonstrated that angiogenesis is suppressed under the presence of high conc
Autor:
Ken Ichiro Hashimoto, Naomi Yoshida, Tadashi Kasahara, Yoshiko Sonoda, Megumi Funakoshi-Tago, Akiko Rokudai, Masakazu Yamakado, Eriko Aizu-Yokota
Publikováno v:
Cellular signalling. 18(7)
We previously demonstrated that focal adhesion kinase (FAK)-overexpressed (HL-60/FAK) cells have marked resistance against various apoptotic stimuli such as oxidative stress, ionizing radiation and TNF-receptor-induced ligand (TRAIL) compared with ve
Autor:
Ryoko Kuniyoshi, Kiyohiko Hatake, Yuji Mishima, Yasuhito Terui, Kengo Takeuchi, Yuko Mishima, Kiyotsugu Kojima, Masahiro Yokoyama, Natsuhiko Sugimura, Akiko Rokudai
Publikováno v:
Blood. 108:2369-2369
Introduction: Rituximab was the first chimeric antibody that is most frequently used for CD20-posistive B-cell lymphomas and gives better response and prognosis. However, resistance to rituximab is one of the important issues to be clarified in the i